Sector Expert: Daniel Carlson

Tailwinds Research

Image: Daniel Carlson

Daniel Carlson is the founder and managing member of Tailwinds Research Group and its parent company DFC Advisory Services, which is a licensed registered investment advisor (CRD # 297209). Tailwinds is a microcap focused research company that provides research on and consults to over 20 emerging growth companies in the technology and life sciences arenas. DFC Advisory Services is an RIA that manages money dedicated to investing in the companies covered by Tailwinds. For more information on these two companies and their track record, please see www.tailwindsresearch.com. Prior to founding these two entities, Dan spent many years working with small public companies, having been CFO of two public companies and helping finance many others. A 1989 graduate from Tufts University with a degree in Economics, Danís formative years in business were spent as an equity trader, first on the Pacific Coast Stock Exchange then on the buyside at several multi-billion dollar firms.

Subscribe to
Streetwise Reports

Companies Commented On

  • Allergan Inc.
  • Anixa Biosciences Inc.
  • Atomera Inc.
  • Bioasis Technologies Inc.
  • Catasys Inc.
  • Harrow Health Inc.
  • HyreCar
  • Imprimis Pharmaceuticals Inc.
  • Patriot One Technologies Inc.
  • Provention Bio
  • Resonant Inc.
  • RumbleOn Inc.
  • Summit Wireless Inc.
  • Vicor Corp.


Recent Interviews

Why Provention Bio Is in My Portfolio (8/23/19)
moneyinbeaker580

Orphan drug and breakthrough therapy status, which could mean this company's lead candidate is on the FDA fast track, translates to huge opportunities for both those suffering from diabetes and investors, says Daniel Carlson of Tailwinds Research.

Atomera: When Will Revenues Start? (8/9/19)
Board circuit

Daniel Carlson of Tailwinds Research delves into the company's earnings report.

Resonant's Cup Is Half-Empty. . .Or, Is It Half-Full? (8/8/19)
Stock technology

Daniel Carlson of Tailwinds Research digs into the issues and potential of this company, which received an infusion of cash from a major Japanese manufacturer.



Due to permission requirements, not all quotes are shown.